Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2219

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 2219
---
 cover our product candidates,
intermediates used in the manufacture of our product candidates or our materials generally, aspects of our formulations or methods of
use, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained
a license or sublicense or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such
a license or sublicense may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license
or sublicense to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates
may be impaired or delayed, which could in turn significantly harm our business. Even if we obtain a license or sublicense, it may be
nonexclusive, thereby giving our competitors access to the same technologies licensed or sublicensed to us. In addition, if the breadth
or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating
with us to license, sublicense, develop or commercialize current or future product candidates.

Parties
making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further
develop and commercialize our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation
expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement
against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, obtain
one or more licenses or sublicenses from third parties, pay royalties or redesign our infringing products, which may be impossible or
require substantial time and monetary expenditure. We cannot predict whether any such license or sublicense would be available at all
or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain
licenses or sublicenses from third parties to advance our research or allow commercialization of our product candidates. We may fail
to obtain any of these licenses or sublicenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable
to further develop and commercialize our product candidates, which could harm our business significantly.

Third
parties may assert that our employees, consultants or advisors have wrongfully used or disclosed confidential information or misappropriated
trade secrets.

As
is common in the